1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration.

IF 2.8 3区医学 Q1 OPHTHALMOLOGY

Eye Pub Date : 2025-05-01 Epub Date: 2025-01-25 DOI:10.1038/s41433-025-03616-5

Imran Karim Janmohamed, Adeel Mushtaq, Jamil Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, Anibe Ata, Henrietta Monye, Zakariya Jarrar, Shabeeba Hannan, Luke Membrey

{"title":"1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration.","authors":"Imran Karim Janmohamed, Adeel Mushtaq, Jamil Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, Anibe Ata, Henrietta Monye, Zakariya Jarrar, Shabeeba Hannan, Luke Membrey","doi":"10.1038/s41433-025-03616-5","DOIUrl":null,"url":null,"abstract":"Background and objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and treatment intervals were assessed at baseline, 6, and 12 months.Results: One hundred eighty-four patients (215 eyes) were included. Patients had received a median of 18 (interquartile range [IQR] 10-28.5) anti-VEGF injections per eye over an average of 5.02 ± 11.82 years before switch. An average of 8.63 ± 2.2 faricimab injections were administered per eye over an average follow-up of 12.19 ± 2.70 months. Median BCVA decreased from 70 ETDRS letters (IQR 55-76) at baseline to 62 (IQR 47-76) at 12 months (p = 0.0038). Median CMT improved from 259.5 μm (IQR 223-299.75) at baseline to 232 μm (202.0-272.5) at 12 months (p < 0.0001). At the last follow-up, 40.2% of eyes were dry on OCT. The median dosing interval doubled from 4 weeks (IQR 4-4) to 8 weeks (IQR 6-10) with faricimab (p < 0.0001). 47.4% and 16.3% of eyes achieved treatment intervals of ≥8-12 weeks and ≥12 weeks, respectively. Three events of uveitis were noted following the loading phase.Conclusions: This real-world study demonstrates that faricimab maintains vision and achieves significant anatomical improvements in treatment-experienced nAMD patients. The extended treatment intervals could significantly reduce the burden on patients and healthcare resources.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":"1344-1348"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044001/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-025-03616-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.

Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and treatment intervals were assessed at baseline, 6, and 12 months.

Results: One hundred eighty-four patients (215 eyes) were included. Patients had received a median of 18 (interquartile range [IQR] 10-28.5) anti-VEGF injections per eye over an average of 5.02 ± 11.82 years before switch. An average of 8.63 ± 2.2 faricimab injections were administered per eye over an average follow-up of 12.19 ± 2.70 months. Median BCVA decreased from 70 ETDRS letters (IQR 55-76) at baseline to 62 (IQR 47-76) at 12 months (p = 0.0038). Median CMT improved from 259.5 μm (IQR 223-299.75) at baseline to 232 μm (202.0-272.5) at 12 months (p < 0.0001). At the last follow-up, 40.2% of eyes were dry on OCT. The median dosing interval doubled from 4 weeks (IQR 4-4) to 8 weeks (IQR 6-10) with faricimab (p < 0.0001). 47.4% and 16.3% of eyes achieved treatment intervals of ≥8-12 weeks and ≥12 weeks, respectively. Three events of uveitis were noted following the loading phase.

Conclusions: This real-world study demonstrates that faricimab maintains vision and achieves significant anatomical improvements in treatment-experienced nAMD patients. The extended treatment intervals could significantly reduce the burden on patients and healthcare resources.

查看原文本刊更多论文

faricimab治疗新生血管性年龄相关性黄斑变性的1年实际疗效

背景和目的：Faricimab是一种靶向VEGF-A和血管生成素-2的双特异性抗体，在治疗新生血管性年龄相关性黄斑变性（nAMD）方面显示出前景。本研究评估了faricimab治疗经历过治疗的nAMD患者的1年预后。方法：这项单中心回顾性队列研究纳入了之前接受过nAMD治疗的患者，这些患者在2022年11月至2024年3月期间改用法昔单抗。在基线、6个月和12个月时评估最佳矫正视力（BCVA）、中央黄斑厚度（CMT）和治疗间隔。结果：纳入184例患者（215只眼）。在转换前的平均5.02±11.82年期间，患者每只眼接受抗vegf注射的中位数为18（四分位间距[IQR] 10-28.5）。在平均12.19±2.70个月的随访期间，每只眼睛平均注射8.63±2.2次法利西单抗。中位BCVA从基线时的70个ETDRS字母（IQR 55-76）降至12个月时的62个（IQR 47-76）（p = 0.0038）。中位CMT从基线时的259.5 μm （IQR 223-299.75）改善到12个月时的232 μm (202.0-272.5) (p)。结论：这项现实世界的研究表明，faricimab在治疗经验丰富的nAMD患者中维持了视力并实现了显着的解剖改善。延长治疗间隔可以显著减轻患者和医疗资源的负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eye 医学-眼科学

CiteScore

6.40

自引率

5.10%

发文量

481

审稿时长

3-6 weeks

期刊介绍： Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists. Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.